HP
BCAX

HealthInvest Partners’s Bicara Therapeutics BCAX Stock Holding History

HealthInvest Partners’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.32M Buy
1,169,634
+1,058,271
+950% +$18.2M 0.75% 37
2025
Q4 		$1.87M Sell
111,363
-92,392
-45% -$1.58M 0.6% 37
2025
Q3 		$342K Buy
203,755
+56,375
+38% +$631K 1.27% 27
2025
Q2 		$1.37M Buy
147,380
+27,547
+23% +$328K 0.59% 34
2025
Q1 		$1.56M Buy
+119,833
New +$1.59M 0.69% 31

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

HealthInvest Partners's BCAX Position: Q1 2026 in Review

HealthInvest Partners increased its Bicara Therapeutics (BCAX) stake by 950% in Q1 2026, buying an estimated $18.2M and bringing the position to 1,169,634 shares worth $2.32M. The position accounts for 0.75% of the portfolio, ranked #37.

HealthInvest Partners first reported a position in BCAX in Q1 2025 and has held it in 5 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • HealthInvest Partners held 1,169,634 shares of Bicara Therapeutics worth $2.32M as of Q1 2026.
  • HealthInvest Partners bought 1,058,271 Bicara Therapeutics shares in Q1 2026, an estimated $18.2M.
  • Bicara Therapeutics made up 0.75% of HealthInvest Partners's portfolio in Q1 2026, its #37 holding.
  • HealthInvest Partners first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on HealthInvest Partners's 13F filing for Q1 2026, filed 11 May 2026.